Their results confirmed that KRAS2 and BRAF mutations do not co-exist in HNSCC; hence, oncogenic KRAS2 activates wild-type BRAF, but mutated BRAF does not require KRAS2 for activation, suggesting simultaneous mutations may be redundant [65]. This evidence concerns the gene KRAS and head and neck squamous cell carcinoma.